Case series:CAR-T treatment

2 trials

Sponsors

Beijing Shijitan Hospital,Capital Medical University, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

Conditions

Relapsed and refractory hematological malignanciesRelapsed or Refractory B-cell Lymphoma

Early Phase 1

Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy for Relapsed or Refractory B-cell Lymphoma

Active, not recruitingChiCTR1900024632

Beijing Shijitan Hospital,Capital Medical UniversityRelapsed or Refractory B-cell Lymphoma

Start: 2019-08-01Updated: 2019-07-22

Unknown Phase

CAR-T cells in the treatment of relapsed and refractory hematological malignancies

RecruitingChiCTR1900025419

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical SciencesRelapsed and refractory hematological malignancies

Start: 2017-01-01Updated: 2019-08-27

Related Papers

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T‐Cell Infusion: A Case Report With Mechanistic Insight

Hematological Oncology2026-06-24

Antigen-switch and BCR-axis–enriched multi-target CAR T re-infusion after prior CAR T failure in R/R B-cell NHL.

Journal of Clinical Oncology2026-05-28

Overcoming resistance to prior CAR-T therapy: Efficacy and safety of a sequential, multi-antigen targeted CAR T-cell strategy in B-cell NHL.

Journal of Clinical Oncology2026-05-27

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma

Journal for ImmunoTherapy of Cancer2024-04-0125 citations

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

Blood2022-11-15

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.

2022-03-2227 citations

[Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].

PubMed2021-05-143 citations

Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood2020-11-041 citations